Nevado: until NIPT technology offers CNV detection across the genome, and less expensive, CMA as invasive tool is impt. #MDxE17
9:07am April 10th 2017 via Hootsuite
Julian Nevado (INGEMM, Spain) aCGH as a first-tier test in all invasive prenatal samples #MDxE17
9:06am April 10th 2017 via Hootsuite
In beautiful Lisbon this week for CHI Molecular Diagnostics Europe https://t.co/psvbb2vaUS #MDxE17 A few notes ff on Prenatal MDx
9:05am April 10th 2017 via Hootsuite
23andMe Rides Again: FDA Clears Genetic Tests To Predict Disease Risk | Forbes https://t.co/uvLZ0DqEbQ
8:56am April 10th 2017 via Hootsuite
"The Breakdown of Biomedical Research" - agree with Herper RT @matthewherper: This seems way overdone. https://t.co/0XCtBuaTVr via @WSJ
2:05pm April 8th 2017 via Hootsuite
Walt Mossberg is retiring in June - The Verge https://t.co/zoautudbO6
12:49pm April 8th 2017 via Hootsuite
Wrongful Death Suit Awaits Input From South Carolina Supreme Court | GenomeWeb ($) https://t.co/FCNkT9fyiH
2:51pm April 7th 2017 via Hootsuite
RT @SeraCare: What has been the biggest advance in #genomics in the last 5 years? https://t.co/cxYU7nCg35 https://t.co/sSnMgq1gJq
9:39am April 7th 2017 via Hootsuite
@niazafghan Of course! If you'd like to correspond via email my personal address is dale (at) https://t.co/yXJMjujFNx
9:38am April 7th 2017 via Hootsuite in reply to niazafghan
Michael Caligiuri (The Ohio State Univ OH): Vision for the Future #AACR17 Spotlight cancer health disparities research; preserve workforce
1:19pm April 5th 2017 via Hootsuite
Davidson: Carpten points out that of 333 prostate cancer samples in TCGA, only 25 are from Af Americans #AACR17
1:17pm April 5th 2017 via Hootsuite
Davidson: John Carpten's diagram - precision prevention, precision prognostics, precision therapy. #AACR17
1:16pm April 5th 2017 via Hootsuite
Davidson: Racial and ethnic minorities are still underrepresented in genomic ressearch; 1/3 of Af Americans would participate in PMI #AACR17
Davidson: Prec med a double-edged sword - could hurt by further exacerbating access due to existing healthcare disparaties #AACR17
1:15pm April 5th 2017 via Hootsuite
Davidson: The promise of immunoprevention - already here with HPV, HBV vaccines. Two ex, a-MUC1 vaccine, low-grade glioma vaccine #AACR17
1:11pm April 5th 2017 via Hootsuite
ICYMI the @pacibio poster at #AACR17 looking at low-freq somatic variant detection using CCS on Sequel https://t.co/WZMSxw3PUW and @SeraCare
1:07pm April 5th 2017 via Hootsuite
ICYMI - Quest Diagnostics poster at #AACR17 https://t.co/aRpVj1vmhD using @SeraCare reference materials for solid tumor
1:04pm April 5th 2017 via Hootsuite
Davidson: Tomasetti's work may be a guiding principle; possible new hallmarks include non-mut epigenetics, microbiome as 'enabling' #AACR17
1:02pm April 5th 2017 via Hootsuite
Davidson: Precancer ref just published https://t.co/bNTAnSB4s1 #AACR17
1:01pm April 5th 2017 via Hootsuite
Davidson: Pre-Cancer Genome Atlas? '17 JAMA https://t.co/xBVtUF7mhN county-by-county measure of cancer incidence #AACR17
1:00pm April 5th 2017 via Hootsuite
Nancy Davidson (Univ WA) Early detection and prevention research #AACR17 Starts with acknowledgements.
12:59pm April 5th 2017 via Hootsuite
@niazafghan Here's the link: https://t.co/bz5NaSkDBn
12:58pm April 5th 2017 via Hootsuite in reply to niazafghan
@niazafghan Hi - not sure if you read my blog at https://t.co/yXJMjujFNx - it's for targeted, but pretty exciting… https://t.co/pdF2j7wKcZ
12:57pm April 5th 2017 via Hootsuite in reply to niazafghan
Jaffee: Rational combinations of Rx, leading to improved response rates. #AACR17
12:56pm April 5th 2017 via Hootsuite
Jaffee: Conclude a broadening of tumor types for IO, targeted Rx. Basic discoveries now translating into real benefit #AACR17
Jaffee: Advances in use of PARPi; PI3Ki (BYL719) and Olaparib in Ov ca, waterfall shows sig partial responders #AACR17
12:55pm April 5th 2017 via Hootsuite
Jaffee: Ph II SUMMIT study for pan-HER mutated cancers (multiple types) #AACR17
12:53pm April 5th 2017 via Hootsuite
Jaffee: Advances in HER2 targeted Rx: Lapatinib + traztuzumab in HER2+ KRAS WT mCRC, met primary endpt #AACR17
12:52pm April 5th 2017 via Hootsuite
Jaffee: Ph 2 of indoximod + pembrolizumab for adv melanoma: ORR 59% #AACR17
12:49pm April 5th 2017 via Hootsuite
Jaffee: Ph Ia for mTNBC w/atelzolizumab, responders: 100% alive after 1y, 38% for nonresp. Correlated with immune response #AACR17
12:48pm April 5th 2017 via Hootsuite
Jaffee: (That was for single nivolumab). OS for nivo/ipi in melanoma. Merkel Cell Carcinoma (MCC), Ph 1/2 ORR was 64% #AACR17
12:45pm April 5th 2017 via Hootsuite
Elizabeth Jaffee (Johns Hopkins MD): Therapeutics #AACR17 Long-term OS data from PD-1 checkpoint trials; 5-y OS was 16%, historical 4%
12:44pm April 5th 2017 via Hootsuite
Polyak: May be able to modulate fitness effects of cancer-assoc'd mutations by manipulating the microenvironment #AACR17
12:41pm April 5th 2017 via Hootsuite
Polyak: Cancer and luck: an adaptive landscape, where aging/damage alters this. Thus looking beyond mutations: context-dep selection #AACR17
12:40pm April 5th 2017 via Hootsuite
Polyak: First dual CD19/CD22 bispecific CART should decrease resistance due to antigen loss #AACR17
12:38pm April 5th 2017 via Hootsuite
Polyak: First report of activation of tumor neoantigen-spec T-cells in solid cancer w/personalized peptide vaccine from WES analysis #AACR17
Polyak: Microbiome and anti-tumor immunity: renal ca pts on antibiotics have lower anti-PD-1 response. #AACR17
12:37pm April 5th 2017 via Hootsuite
Polyak: Human error rate is constant (about 4%), Google data indicating machine learning rate is decreasing to be better now #AACR17
12:35pm April 5th 2017 via Hootsuite
Polyak: AI/Machine learning - 2.5 Exabytes of data is produced every day. Pathology is 'critical for precision medicine' #AACR17
12:34pm April 5th 2017 via Hootsuite
Polyak: Getz (Broad) after >2,700 'still more whole genomes are needed'. many discoveries. Dreidax (Heidelberg) Enh hijacking #AACR17
12:33pm April 5th 2017 via Hootsuite
Polyak: Looking at gene class dependency, Hahn (Broad) looking at different categories of dependencies of classes beyond mutations #AACR17
12:31pm April 5th 2017 via Hootsuite
Polyak: Theranostics via Bhujwalla at Hopkins - photoimmunotherapy, after single-dose of light to activate agent in mice #AACR17
12:29pm April 5th 2017 via Hootsuite
Polyak: miRNA in circ exosomes - '16 JCI Insight ref https://t.co/jWs519LuUT #AACR17
12:28pm April 5th 2017 via Hootsuite
Polyak: Diehn showing ctDNA av 6mos before clinical progression; sensitivity 'being perfected in the past few years' #AACR17
12:26pm April 5th 2017 via Hootsuite
Polyak: Velculescu showed ctDNA dynamics during immune checkpoint blockade (unpublished, do not post) Primary vs acquired resist #AACR17
Polyak: #AACR17 (For background, I wrote up this work a few years ago https://t.co/WFJVW7U7C7 great to see it applied)
12:25pm April 5th 2017 via Hootsuite
Polyak Lymph node, tumor, blood, looking at CyTOF (Fluidigm). Looking at activation, differentiation #AACR17
12:24pm April 5th 2017 via Hootsuite
Polyak: Shares work from Nick Navins group (unpublished, do not post) very interesting; Dana Pe'er w/ breast cancer immune atlas #AACR17
12:23pm April 5th 2017 via Hootsuite
Polyak: New method of single-cell library prep without preamplification '17 Nature Methods https://t.co/ukE4BfEWkH #AACR17
12:22pm April 5th 2017 via Hootsuite
Polyak: single-cell profiling; non-invasive detection (both liquid biopsy, molecular imaging), CRISPR, 4D chromatin, AI #AACR17
12:20pm April 5th 2017 via Hootsuite
